Are Ortikos and Tysabri the Same Thing?
Ortikos is used to treat mild to moderate active Crohn's disease involving the ileum and/or the ascending colon, in patients 8 years and older; and for maintenance of clinical remission of mild to moderate Crohn's disease involving the ileum and/or the ascending colon for up to 3 months in adults.
Tysabri is used to treat moderate to severe Crohn's disease and is usually given after other Crohn's disease medications have been tried without successful treatment of this condition. Tysabri is also used to treat relapsing forms of multiple sclerosis.
Side effects of Tysabri that are different from Ortikos include joint or muscle pain, redness or irritation at the injection site, swelling hands/feet/ankles, changes in menstrual cycle, painful menstrual cramps, diarrhea, skin rash, depression, and cold symptoms such as stuffy nose, sneezing, or sore throat.
Both Ortikos and Tysabri may interact with cyclosporine.
Tysabri may also interact with medicines that may affect the immune system such as interferon, sirolimus, tacrolimus, basiliximab, efalizumab, muromonab-CD3, mycophenolate mofetil, azathioprine, leflunomide, etanercept, and chemotherapy or radiation treatments.
What Are Possible Side Effects of Ortikos?
Common side effects of Ortikos include:
- respiratory infection,
- back pain,
- abdominal pain,
- gas (flatulence),
- fatigue, and
What Are Possible Side Effects of Tysabri?
Common side effects of Tysabri include:
- tired feeling,
- joint or muscle pain,
- redness or irritation at the injection site,
- swelling hands/feet/ankles,
- changes in menstrual cycle,
- stomach pain,
- skin rash,
- painful menstrual cramps, or
- cold symptoms such as stuffy nose, sneezing, or sore throat.
Tell your doctor if you have side effects while Tysabri is being given or shortly after your treatment is finished (infusion reaction) including:
What Is Ortikos?
Ortikos (budesonide) is a corticosteroid indicated for treatment of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon, in patients 8 years and older; and maintenance of clinical remission of mild to moderate Crohn' disease involving the ileum and/or the ascending colon for up to 3 months in adults.
What Is Tysabri?
Tysabri (natalizumab) is a monoclonal antibody used in to treat relapsing forms of multiple sclerosis. Tysabri is also used to treat moderate to severe Crohn's disease in adults. Tysabri is usually given after other Crohn's disease medications have been tried without successful treatment of this condition.
What Drugs Interact With Ortikos?
Ortikos may interact with CYP3A4 Inhibitors (e.g., ketoconazole, grapefruit juice, itraconazole, ritonavir, indinavir, saquinavir, erythromycin, and cyclosporine). Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Ortikos; it may harm a fetus.
What Drugs Interact With Tysabri?
Tysabri may interact with other medicines, especially those that may affect the immune system such as: interferon, cyclosporine, sirolimus, tacrolimus, basiliximab, efalizumab, muromonab-CD3, mycophenolate mofetil, azathioprine, leflunomide, etanercept, or chemotherapy or radiation treatments.
How Should Ortikos Be Taken?
The recommended adult dosage of Ortikos for mild to moderate active Crohn's disease is 9 mg once daily for up to 8 weeks; repeat 8-week treatment courses recurring episodes of active disease. The recommended dosage of Ortikos for pediatric patients 8 to 17 years who weigh more than 25 kg is 9 mg once daily for up to 8 weeks, followed by 6 mg once daily in the morning for 2 weeks.
How Should Tysabri Be Taken?
The recommended dose of Tysabri for multiple sclerosis or Crohn's disease is 300 mg intravenous infusion over one hour every four weeks.
All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).
Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.
Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.
The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.
As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.
Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.
If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.
You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.
FDA. Ortikos Drug Information.
Biogen. Tysabri Product Monograph.